Based on information provided by the company, Ipsen carried out transactions on its shares between November 10 and November 14, 2025. The total daily volume of traded shares and the average weighted acquisition price were recorded across several markets, including AQEU, CEUX, TQEX, and XPAR. For instance, on November 10, 300 shares were acquired on the AQEU market at a price of €127.30, while on the CEUX market, 1,000 shares were acquired at €127.60.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
On November 11, 500 shares were traded on the CEUX market at a price of €128.90, and 2,330 shares were acquired on XPAR at a price of €128.80854. On November 12, transactions included 600 shares on AQEU at €130.05 and 1,600 shares on XPAR at €129.932. On November 13, the trading volume on CEUX was 2,000 shares at €130.36540, while the XPAR market recorded 1,527 shares at €130.11657. On November 14, 2,500 shares were traded on XPAR at a price of €130.55904.
These purchases were made in accordance with the conditions of Article 5 of the MAR regulation, the company specifies. These transactions are part of Ipsen's strategy of buying back its own shares, a strategy often used for various financial reasons, including capital distribution to shareholders or stabilizing the stock price. The press release includes details on the markets and prices applied to each transaction.
SectorSanté · Vaccins et laboratoires de recherche›Industrie Pharmaceutique
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1074.9M€
Guidance from the release
Ipsen a réalisé un excellent début d'année 2026.
Croissance soutenue grâce aux trois aires thérapeutiques.
Risks mentioned
pression réglementaire anticipée sur de nouveaux médicaments
concurrence accrue sur Somatuline à cause des génériques
Opportunities identified
croissance des ventes totales du Groupe supérieure à 13,0 %
lancement de trois nouveaux programmes en phase avancée
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
